Ernexa Therapeutics Inc. Gain (Loss) on Extinguishment of Debt
Ernexa Therapeutics Inc. (ERNA) reported Gain (Loss) on Extinguishment of Debt of $41.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-08-06
- Ernexa Therapeutics Inc. gain (loss) on extinguishment of debt for the quarter ending 2026-06-30 was $41.00K.
- Ernexa Therapeutics Inc. gain (loss) on extinguishment of debt for the quarter ending 2025-12-31 was $31.00K.
- Ernexa Therapeutics Inc. gain (loss) on extinguishment of debt for the quarter ending 2025-09-30 was $734.00K.
- Ernexa Therapeutics Inc. gain (loss) on extinguishment of debt for the quarter ending 2025-06-30 was -$500.00K.
- Ernexa Therapeutics Inc. gain (loss) on extinguishment of debt for fiscal 2025 was $765.00K.
- Ernexa Therapeutics Inc. gain (loss) on extinguishment of debt for fiscal 2024 was -$22.44M.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $41.00K 10-Q · filed 2026-08-06 | $41.00K 10-Q · filed 2026-08-06 | ||
| 2025-12-31 | $31.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $765.00K derived: sum of 2 quarters · filed 2026-03-13 | $265.00K derived: sum of 3 quarters · filed 2026-03-13 | $765.00K 10-K · filed 2026-03-13 |
| 2025-09-30 | $734.00K 10-Q · filed 2025-11-07 | $234.00K derived: sum of 2 quarters · filed 2025-11-07 | $734.00K 10-Q · filed 2025-11-07 | -$5.07M derived: sum of 4 quarters · filed 2026-03-13 |
| 2025-06-30 | -$500.00K 10-Q · filed 2025-08-13 | -$5.80M 10-Q · filed 2025-08-13 | -$5.80M derived: sum of 3 quarters · filed 2026-03-13 | -$28.24M derived: sum of 4 quarters · filed 2026-03-13 |
| 2025-03-31 | -$5.30M 10-Q · filed 2025-05-07 | -$5.30M derived: sum of 2 quarters · filed 2026-03-13 | -$27.74M derived: sum of 3 quarters · filed 2026-03-13 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$22.44M derived: sum of 2 quarters · filed 2026-03-13 | -$22.44M 10-K · filed 2026-03-13 | |
| 2024-09-30 | -$22.44M 10-Q · filed 2025-11-07 | -$22.44M 10-Q · filed 2025-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |